# Greenwich LifeSciences, Inc.: financial statements, quarterly

GLSI · Nasdaq · CIK 1799788 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/glsi.md) · [Financials](/companies/glsi/financials.md) · [Filings](/companies/glsi/filings.md) · [Insiders](/companies/glsi/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/glsi/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $k | [2,158](/filings/0001493152-24-045938.md) | [2,333 d](/filings/0001641172-25-004819.md) | [2,195](/filings/0001641172-25-011731.md) | [2,308](/filings/0001641172-25-024066.md) | [2,292](/filings/0001493152-25-023539.md) | [8,686 d](/filings/0001493152-26-026651.md) | [2,271](/filings/0001493152-26-027150.md) | [3,416](/filings/0001493152-26-037147.md) | [3,267](/filings/0001493152-26-026651.md) | [8,266 d](/filings/0001493152-26-026651.md) | [5,208](/filings/0001493152-26-027150.md) | [3,559](/filings/0001493152-26-037147.md) |
| Operating income | $k | [(2,503)](/filings/0001493152-24-045938.md) | [(2,836) d](/filings/0001641172-25-004819.md) | [(2,537)](/filings/0001641172-25-011731.md) | [(2,661)](/filings/0001641172-25-024066.md) | [(2,729)](/filings/0001493152-25-023539.md) | [(9,710) d](/filings/0001493152-26-026651.md) | [(2,769)](/filings/0001493152-26-027150.md) | [(3,769)](/filings/0001493152-26-037147.md) | [(4,175)](/filings/0001493152-25-023539.md) | [(7,945) d](/filings/0001493152-26-026651.md) | [(5,726)](/filings/0001493152-26-027150.md) | [(4,022)](/filings/0001493152-26-037147.md) |
| Net income | $k | [(2,392)](/filings/0001493152-24-045938.md) | [(2,747) d](/filings/0001641172-25-004819.md) | [(2,473)](/filings/0001493152-25-023539.md) | [(2,607)](/filings/0001493152-25-023539.md) | [(2,669)](/filings/0001493152-25-023539.md) | [(9,666) d](/filings/0001493152-26-026651.md) | [(2,745)](/filings/0001493152-26-037147.md) | [(3,749)](/filings/0001493152-26-037147.md) | [(3,711)](/filings/0001493152-26-026651.md) | [(9,154) d](/filings/0001493152-26-026651.md) | [(5,657)](/filings/0001493152-26-037147.md) | [(3,949)](/filings/0001493152-26-037147.md) |
| Diluted EPS | $ per share | [(0.19)](/filings/0001493152-24-045938.md) | not reported | [(0.19)](/filings/0001641172-25-011731.md) | [(0.20)](/filings/0001641172-25-024066.md) | [(0.20)](/filings/0001493152-25-023539.md) | not reported | [(0.21)](/filings/0001493152-26-027150.md) | [(0.28)](/filings/0001493152-26-037147.md) | [(0.27)](/filings/0001493152-26-026651.md) | not reported | [(0.39)](/filings/0001493152-26-027150.md) | [(0.27)](/filings/0001493152-26-037147.md) |
| Basic EPS | $ per share | [(0.19)](/filings/0001493152-24-045938.md) | not reported | [(0.19)](/filings/0001641172-25-011731.md) | [(0.20)](/filings/0001641172-25-024066.md) | [(0.20)](/filings/0001493152-25-023539.md) | not reported | [(0.21)](/filings/0001493152-26-027150.md) | [(0.28)](/filings/0001493152-26-037147.md) | [(0.27)](/filings/0001493152-26-026651.md) | not reported | [(0.39)](/filings/0001493152-26-027150.md) | [(0.27)](/filings/0001493152-26-037147.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [9.1](/filings/0001493152-23-037702.md) | [7.0](/filings/0001641172-25-004819.md) | [5.5](/filings/0001493152-24-020710.md) | [7.2](/filings/0001493152-24-032278.md) | [5.8](/filings/0001493152-24-045938.md) | [4.1](/filings/0001493152-26-026651.md) | [2.7](/filings/0001641172-25-011731.md) | [3.1](/filings/0001641172-25-024066.md) | [3.8](/filings/0001493152-25-023539.md) | [6.2](/filings/0001493152-26-026651.md) | [10.5](/filings/0001493152-26-027150.md) | [8.9](/filings/0001493152-26-037147.md) |
| Current assets | $m | not reported | not reported | not reported | not reported | not reported | [4.1](/filings/0001493152-26-026651.md) | not reported | not reported | not reported | [6.2](/filings/0001493152-26-037147.md) | [10.5](/filings/0001493152-26-027150.md) | [8.9](/filings/0001493152-26-037147.md) |
| Total assets | $m | [9.1](/filings/0001493152-23-037702.md) | [7.0](/filings/0001641172-25-004819.md) | [5.5](/filings/0001493152-24-020710.md) | [7.2](/filings/0001493152-24-032278.md) | [5.8](/filings/0001493152-24-045938.md) | [4.1](/filings/0001493152-26-026651.md) | [2.8](/filings/0001641172-25-011731.md) | [3.1](/filings/0001641172-25-024066.md) | [3.8](/filings/0001493152-25-023539.md) | [6.2](/filings/0001493152-26-037147.md) | [10.5](/filings/0001493152-26-027150.md) | [8.9](/filings/0001493152-26-037147.md) |
| Current liabilities | $m | [0.3](/filings/0001493152-23-037702.md) | [0.3](/filings/0001641172-25-004819.md) | [0.4](/filings/0001493152-24-020710.md) | [1.4](/filings/0001493152-24-032278.md) | [0.8](/filings/0001493152-24-045938.md) | [3.2](/filings/0001493152-26-026651.md) | [1.4](/filings/0001641172-25-011731.md) | [1.7](/filings/0001641172-25-024066.md) | [1.6](/filings/0001493152-25-023539.md) | [5.8](/filings/0001493152-26-037147.md) | [5.2](/filings/0001493152-26-027150.md) | [5.8](/filings/0001493152-26-037147.md) |
| Total liabilities | $m | [0.3](/filings/0001493152-23-037702.md) | [0.3](/filings/0001641172-25-004819.md) | [0.4](/filings/0001493152-24-020710.md) | [1.4](/filings/0001493152-24-032278.md) | [0.8](/filings/0001493152-24-045938.md) | [3.2](/filings/0001493152-26-026651.md) | [2.6](/filings/0001493152-26-026651.md) | [2.5](/filings/0001493152-26-026651.md) | [2.0](/filings/0001493152-26-026651.md) | [5.8](/filings/0001493152-26-037147.md) | [5.2](/filings/0001493152-26-027150.md) | [5.8](/filings/0001493152-26-037147.md) |
| Shareholders' equity | $m | [8.9](/filings/0001493152-24-045938.md) | [6.7](/filings/0001493152-26-026651.md) | [5.1](/filings/0001493152-25-023539.md) | [5.9](/filings/0001493152-25-023539.md) | [5.0](/filings/0001493152-25-023539.md) | [0.9](/filings/0001493152-26-037147.md) | [0.2](/filings/0001493152-26-037147.md) | [0.6](/filings/0001493152-26-037147.md) | [2.2](/filings/0001493152-25-023539.md) | [0.4](/filings/0001493152-26-037147.md) | [5.3](/filings/0001493152-26-037147.md) | [3.1](/filings/0001493152-26-037147.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,801) d](/filings/0001493152-24-045938.md) | [(2,154) d](/filings/0001641172-25-004819.md) | [(1,783)](/filings/0001641172-25-011731.md) | [(1,048) d](/filings/0001641172-25-024066.md) | [(2,584) d](/filings/0001493152-25-023539.md) | [(1,852) d](/filings/0001493152-26-026651.md) | [(1,834)](/filings/0001493152-26-027150.md) | [(2,233) d](/filings/0001493152-26-037147.md) | [(2,671) d](/filings/0001493152-26-026651.md) | [(3,175) d](/filings/0001493152-26-026651.md) | [(4,702)](/filings/0001493152-26-027150.md) | [(1,940) d](/filings/0001493152-26-037147.md) |
| Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [12.8](/filings/0001493152-23-037702.md) | [12.8](/filings/0001493152-24-020710.md) | [12.8](/filings/0001493152-24-032278.md) | [12.8](/filings/0001493152-24-045938.md) | [12.9](/filings/0001641172-25-011731.md) | [12.9](/filings/0001641172-25-024066.md) | [13.1](/filings/0001493152-25-023539.md) | [13.2](/filings/0001493152-26-027150.md) | [13.4](/filings/0001493152-26-037147.md) | [13.6](/filings/0001493152-25-023539.md) | [14.6](/filings/0001493152-26-027150.md) | [14.6](/filings/0001493152-26-037147.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 14,678,208 at 2026-07-24, from the cover of the [10-Q filed 2026-08-11](/filings/0001493152-26-037147.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.